Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Dylan Grebert Wade"'
In vitro and in vivo drug screens of tumor cells identify novel therapies for high‐risk child cancer
Autor:
Loretta M S Lau, Chelsea Mayoh, Jinhan Xie, Paulette Barahona, Karen L MacKenzie, Marie Wong, Alvin Kamili, Maria Tsoli, Tim W Failes, Amit Kumar, Emily V A Mould, Andrew Gifford, Shu‐Oi Chow, Mark Pinese, Jamie I Fletcher, Greg M Arndt, Dong‐Anh Khuong‐Quang, Carol Wadham, Daniel Batey, Georgina Eden, Peter Trebilcock, Swapna Joshi, Stephanie Alfred, Anjana Gopalakrishnan, Aaminah Khan, Dylan Grebert Wade, Patrick A Strong, Elodie Manouvrier, Lisa T Morgan, Miriam Span, Jin Yi Lim, Roxanne Cadiz, Caitlin Ung, David M Thomas, Katherine M Tucker, Meera Warby, Geoffrey B McCowage, Luciano Dalla‐Pozza, Jennifer A Byrne, Federica Saletta, Andrew Fellowes, Stephen B Fox, Murray D Norris, Vanessa Tyrrell, Toby N Trahair, Richard B Lock, Mark J Cowley, Paul G Ekert, Michelle Haber, David S Ziegler, Glenn M Marshall
Publikováno v:
EMBO Molecular Medicine, Vol 14, Iss 4, Pp n/a-n/a (2022)
Abstract Biomarkers which better match anticancer drugs with cancer driver genes hold the promise of improved clinical responses and cure rates. We developed a precision medicine platform of rapid high‐throughput drug screening (HTS) and patient‐
Externí odkaz:
https://doaj.org/article/f2db646d5831450d847f4d18a36cdea2
Autor:
Jinhan Xie, Paulette Barahona, Michelle Haber, Emily Mould, Andrew J. Gifford, Loretta Lau, Amit Kumar, Timothy W. Failes, Marie Wong-Erasmus, Dylan Grebert-Wade, Greg M. Arndt, M. Emmy M. Dolman, Dong-Anh Khuong-Quang, Chelsea Mayoh, Kanika Bhatia, Shu-Oi Chow, Alvin Kamili, Roxanne Cadiz, Richard B. Lock, Maria Tsoli, Vanessa Tyrrell, David S. Ziegler, Glenn M. Marshall, Penny Athanasatos
Publikováno v:
Cancer Cytopathology. 129:805-818
Background The development of high-throughput drug screening (HTS) using primary cultures provides a promising, clinically translatable approach to tailoring treatment strategies for patients with cancer. However, this has been challenging for solid
In vitro and in vivo drug screens of tumor cells identify novel therapies for high‐risk child cancer
Autor:
Loretta M S Lau, Chelsea Mayoh, Jinhan Xie, Paulette Barahona, Karen L MacKenzie, Marie Wong, Alvin Kamili, Maria Tsoli, Tim W Failes, Amit Kumar, Emily V A Mould, Andrew Gifford, Shu‐Oi Chow, Mark Pinese, Jamie I Fletcher, Greg M Arndt, Dong‐Anh Khuong‐Quang, Carol Wadham, Daniel Batey, Georgina Eden, Peter Trebilcock, Swapna Joshi, Stephanie Alfred, Anjana Gopalakrishnan, Aaminah Khan, Dylan Grebert Wade, Patrick A Strong, Elodie Manouvrier, Lisa T Morgan, Miriam Span, Jin Yi Lim, Roxanne Cadiz, Caitlin Ung, David M Thomas, Katherine M Tucker, Meera Warby, Geoffrey B McCowage, Luciano Dalla‐Pozza, Jennifer A Byrne, Federica Saletta, Andrew Fellowes, Stephen B Fox, Murray D Norris, Vanessa Tyrrell, Toby N Trahair, Richard B Lock, Mark J Cowley, Paul G Ekert, Michelle Haber, David S Ziegler, Glenn M Marshall
Publikováno v:
EMBO Molecular Medicine. 14
Biomarkers which better match anticancer drugs with cancer driver genes hold the promise of improved clinical responses and cure rates. We developed a precision medicine platform of rapid high-throughput drug screening (HTS) and patient-derived xenog
Autor:
Mustafa Syed, Emmy D.G. Fleuren, Chelsea Mayoh, Velimir Gayevskiy, Richard B. Lock, Toby Trahair, Emilie E. Wilkie, Mark Pinese, Heather Tapp, Michelle Haber, Amit Kumar, Inigo Martincorena, Jonathan Baber, Alexandra Sherstyuk, Dylan Grebert-Wade, Rachel Bowen-James, Tracey A. O'Brien, Frank Alvaro, Marie Wong, Andrew J. Gifford, Luciano Dalla-Pozza, David S. Ziegler, Paul Wood, Murray D. Norris, Glenn M. Marshall, Marie Gauthier, David Thomas, Peter Priestley, Mark J. Cowley, Paul G Ekert, Nicholas G. Gottardo, M. Emmy M. Dolman, Vanessa Tyrrell, Dong Anh Khuong-Quang, Geoffry B. McCowage, Andrew S. Moore, Katherine M. Tucker, Emily Mould, Paulette Barahona, Judy Kirk, Loretta Lau, Seong Lin Khaw, Federico Abascal, Meera Warby, Elodie Manouvrier, Patricia Sullivan, Noemi A. Bolanos, Patrick Strong, Jordan R. Hansford
Publikováno v:
Nature medicine. 26(11)
The Zero Childhood Cancer Program is a precision medicine program to benefit children with poor-outcome, rare, relapsed or refractory cancer. Using tumor and germline whole genome sequencing (WGS) and RNA sequencing (RNAseq) across 252 tumors from hi
Autor:
Tim Failes, Meera Warby, Marie Wong, Emily Mould, Andrew J. Gifford, Jayne Murray, Carmela De Santo, Klaartje Somers, Olga B. Chernova, Toby Trahair, Jamie I. Fletcher, Andrei V. Gudkov, Tracey A. O'Brien, Katerina Gurova, Michelle J. Henderson, Laura D. Gamble, Lin Xiao, Murray D. Norris, Maria Tsoli, Glenn M. Marshall, Kathryn Evans, Loretta Lau, Lioubov G. Korotchkina, Ruby Pandher, Richard B. Lock, Denise Yu, Anthony J. Cesare, Mark J. Cowley, Paul G Ekert, Laura Franshaw, Anahid Ehteda, Greg M. Arndt, Marie-Emilie A. Gauthier, Jinhan Xie, Katherine M. Tucker, Paulette Barahona, Sumanth Nagabushan, Aisling O'Connor, Paul Cheng, Amit Kumar, Dylan Grebert-Wade, Aaminah Khan, Alexandra Sherstyuk, Patrick Strong, Chelsea Mayoh, Noemi Fuentes Bolanos, David S. Ziegler, Michelle Haber, Mark R. Burns, David Thomas, Dong Anh Khuong Quang, Francis Mussai, Alvin Kamili, Vanessa Tyrrell
Publikováno v:
Cancer Research. 80:IA13-IA13
Despite the increase in overall child cancer survival rates, pediatric malignancies such as high-risk neuroblastoma, high-risk leukemias (including MLL-translocated infant ALL), and aggressive brain tumors (including DIPG) remain refractory to curren
Autor:
Emily V. Mould, Loretta Lau, Greg Arndt, Paulette Barahona, Mark J. Cowley, Paul Ekert, Tim Failes, Jamie Fletcher, Andrew Gifford, Dylan Grebert-Wade, Michelle Haber, Alvin Kamili, Amit Kumar, Richard B. Lock, Glenn M. Marshall, Chelsea Mayoh, Murray Norris, Tracey O'Brien, Dong Anh Khuong Quang, Patrick Strong, Alexandra Sherstyuk, Toby Trahair, Maria Tsoli, Katherine Tucker, Meera Warby, Marie Wong, Jinhan Xie, David S. Ziegler, Vanessa Tyrrell
Publikováno v:
Cancer Research. 79:3111-3111
Molecular genomics analyses aim to identify subsets of patients harboring actionable aberrations as a pathway to improved targeted treatment selection. However, recent pan-cancer analyses of the molecular landscape of pediatric cancers1,2 have emphas
Autor:
Tracey A. O'Brien, Patrick Strong, Anjana Gopalakrishnan, Katherine M. Tucker, Amit Kumar, Dylan Grebert-Wade, Glenn M. Marshall, Tim Failes, Alexandra Sherstyuk, Vanessa Tyrrell, Richard B. Lock, David S. Ziegler, Caitlin Ung, Marc Cowley, Dong Anh Khuong Quang, Paulette Barahona, Chelsea Mayoh, Toby Trahair, Ornella Tolhurst, Greg M. Arndt, Maria Tsoli, Marie Wong, Michelle Haber, Andrew J. Gifford, Peter Trebilcock, Meera Warby, Loretta Lau, Murray D. Norris, Paul G Ekert, Emily Mould
Publikováno v:
Neuro-Oncology. 21:ii118-ii118
Brain tumours represent the most common solid tumour of childhood and result in significant morbidity and mortality. The Zero Childhood Cancer national child precision medicine program aims to identify targeted therapeutic agents for high-risk paedia